Pharmacokinetics of amlodipine besylate/atorvastatin calcium combination tablet in healthy volunteers
Xiaoyu Wang
Abstract
Xiaoyu Wang
Abstract
OBJECTIVE To study the pharmacokinetics of combination tablets containing amlodipine besylate/atorvastatin calcium in healthy volunteers.METHODS Thirty healthy volunteers(half male-half female)were divided into three groups.Each ten volunteers received a different dose strengths combination tablets(amlodipine/atorvastatin 5 mg/ 10 mg,10 mg/ 10 mg,5 mg/ 20 mg),respectively.The plasma concentrations of amlodipine and atorvastatin were measured by a fully validated LC-MS/MS method.The pharmacokinetic parameters were calculated thereafter in order to study the pharmacokinetic charateristics of amlodipine and atorvastatin in human.RESULTS The following data were the main pharmacokinetic parameters.Amlodipine(5 mg/ 10 mg),Cmax(3.14±0.46)μg·L-1,AUC0-120(131±22);10 mg/10 mg,Cmax(6.85±1.17)μg·L-1,AUC0-120(327±110)μg·h·L-1;5 mg/ 20 mg,Cmax(3.11±0.47)μg·L-1,AUC0-120(130±16)μg·h·L-1;atorvastatin,5 mg/10 mg,Cmax(11.3±6.7)nμg·L-1,AUC0-120(133.8±93.3);10 mg/10 mg,Cmax(16.7±12.1)μg·mL-1,AUC0-120(107.7±60.4)μg·h·L-1;5 mg/20 mg,Cmax(15.0±9.4)μg·L-1,AUC0-120(147.3±59.3)μg·h·L-1.CONCLUSION In all the three dose groups,Cmax and AUC of amlodipine increased in a dose-dependent manner.Atorvastatin coincide with non-linear pharmacokinetic characteristics.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE To study the pharmacokinetics of combination tablets containing amlodipine besylate/atorvastatin calcium in healthy volunteers.METHODS Thirty healthy volunteers(half male-half female)were divided into three groups.Each ten volunteers received a different dose strengths combination tablets(amlodipine/atorvastatin 5 mg/ 10 mg,10 mg/ 10 mg,5 mg/ 20 mg),respectively.The plasma concentrations of amlodipine and atorvastatin were measured by a fully validated LC-MS/MS method.The pharmacokinetic parameters were calculated thereafter in order to study the pharmacokinetic charateristics of amlodipine and atorvastatin in human.RESULTS The following data were the main pharmacokinetic parameters.Amlodipine(5 mg/ 10 mg),Cmax(3.14±0.46)μg·L-1,AUC0-120(131±22);10 mg/10 mg,Cmax(6.85±1.17)μg·L-1,AUC0-120(327±110)μg·h·L-1;5 mg/ 20 mg,Cmax(3.11±0.47)μg·L-1,AUC0-120(130±16)μg·h·L-1;atorvastatin,5 mg/10 mg,Cmax(11.3±6.7)nμg·L-1,AUC0-120(133.8±93.3);10 mg/10 mg,Cmax(16.7±12.1)μg·mL-1,AUC0-120(107.7±60.4)μg·h·L-1;5 mg/20 mg,Cmax(15.0±9.4)μg·L-1,AUC0-120(147.3±59.3)μg·h·L-1.CONCLUSION In all the three dose groups,Cmax and AUC of amlodipine increased in a dose-dependent manner.Atorvastatin coincide with non-linear pharmacokinetic characteristics.
Key concepts: Cmax, Amlodipine, Pharmacokinetics, Atorvastatin, Pharmacology, Chemistry, Medicine, Internal medicine